Introduction
============

*Clostridium difficile* infection (CDI) is a great public health concern in hospital and community settings. In the first decade of the twenty-first century, United States hospitals noted a profound increase in CDI incidence [@B1]. Since then, national standards required hospitals to implement effective infection control interventions and antimicrobial stewardship programs to prevent CDI. Nationally-representative studies now indicate that CDI rates among hospitalized patients might be declining [@B2]. With the decline in CDI incidence in hospitals, there appears to have been a concurrent shift to community-onset CDI [@B3].

A rich and diverse intestinal microbiota prevents CDI; disruption of microbiota, especially due to antibiotic use, can lead to loss of colonization resistance and proliferation of *C. difficile* [@B4],[@B5]. Antibiotic exposure is the most important risk factor in both hospital and community-onset CDI [@B6]-[@B8]. In previous meta-analyses conducted between 1988 and 2009, clindamycin, fluoroquinolones, and cephalosporins had the highest CDI risks [@B6]-[@B8].

Given the change in CDI epidemiology in recent years, more recent data are needed to evaluate the current CDI associations with various antibiotics. The FDA Adverse Event Reporting System (FAERS) provides recent data on CDI and antibiotics [@B9]. The objective of this study is to evaluate CDI associations with antibiotics using FAERS data from 2015 to 2017.

Methods
=======

Data Source
-----------

FAERS is a publicly available database organized into Quarterly Data Files, which contain adverse event reports that were submitted to United States Food and Drug Administration (FDA) [@B9]. FAERS data include patient demographic information (age and sex), drug information (drug name, active ingredient, route of administration, and drug\'s reported role in the event), and reaction information. Each report lists a primary suspected drug with one or more adverse reactions and may include other drugs. Clinical outcomes, such as death and hospitalization, may also be reported.

Study Design
------------

FAERS data from January 1, 2015 to December 31, 2017 were obtained from the FDA. Some adverse event reports were submitted multiple times with updated information. Therefore, duplicate reports were removed by case number, with the most recent submission included in the study. Reports containing drugs which were administered in oral, subcutaneous, intramuscular, intravenous, and parenteral routes were included in the study, while other routes of administration were excluded.

Drug Exposure Definition
------------------------

Each antibiotic was identified in the FAERS drug files by generic and brand names listed in the Drugs\@FDA Database [@B10]. Only drugs with a reported role coded as "PS" (Primary Suspect Drug) or "SS" (Secondary Suspect Drug) were included in this study [@B11]. Antibiotics with less than three CDI reports were excluded from the data analysis [@B12].

Adverse Drug Reaction Definition
--------------------------------

FAERS defines adverse drug reactions using Preferred Terms from the Medical Dictionary for Regulatory Activities (MedDRA). MedDRA includes a hierarchy of terms, which are (from the highest to the lowest) System Organ Classes (SOC), High Level Group Term (HLGT), High Level Term (HLT), Preferred Term (PT), and Lowest Level Term (LLT). Standardised MedDRA Queries (SMQs) are groupings of MedDRA terms, usually at the PT level, which relate to an adverse drug reaction. Pseudomembranous colitis (SMQ), including Preferred Terms "Clostridial infection", "Clostridial sepsis", "Clostridium bacteraemia", "Clostridium colitis", "Clostridium difficile colitis", "Clostridium difficile infection", "Clostridium test positive", "Gastroenteritis clostridial", and "Pseudomembranous colitis" were used to identify CDI cases [@B13]. "Clostridium difficile sepsis", which is a Lowest Level Term, was also used in the study.

Statistical Analysis
--------------------

A disproportionality analysis was performed by calculating Reporting Odds Ratios (RORs) and corresponding 95% confidence intervals (95%CI) for the association between CDI and each antibiotic class or individual antibiotic [@B14]. ROR was calculated as the ratio of the odds of reporting CDI versus all other events for a given drug, compared with these reporting odds for other drugs present in FAERS [@B14]. An association was considered to be statistically significant if the 95%CI did not include 1.0 (see Table [1](#T1){ref-type="table"} for the calculation of ROR and CI) [@B14]. A higher ROR suggests a stronger association between the antibiotic and CDI. A subgroup analysis was performed on patients who were 65 years or older and patients less than 65 years old. The Cochran-Armitage Trend Test was used to assess a change in the trend of CDI reports in patients who took fluoroquinolones from 2004 to 2017. Data analysis was performed using Microsoft Access 2016, Microsoft Excel 2016 (Microsoft Corporation, Redmond, WA), SAS 9.4, and JMP Pro 13.2.1 (SAS Institute, Cary, NC).

Results
=======

After inclusion and exclusion criteria were applied and duplicate reports were removed, FAERS contained a total of 2,042,801 reports from January 1, 2015 to December 31, 2017. There were 5,187 CDI reports from 2015 to 2017, which were included in the data analysis. Female patients represented 61% of CDI patients who had gender information. CDI patients who had age information had a median age (IQR, interquartile range) of 62 (27) years. Please see Table [2](#T2){ref-type="table"} for the gender and age information of patients who were taking various antibiotics.

The lincosamide class had the highest CDI ROR (46.95, 95%CI: 39.49-55.82) among all antibiotic classes included in the study (Figure [1](#F1){ref-type="fig"}). Clindamycin was the only antibiotic in the lincosamide class which met the inclusion criteria. The monobactam class (including aztreonam only) demonstrated the second highest CDI ROR (29.97, 95%CI: 14.60-61.54). The CDI ROR of the trimethoprim-sulfonamides class was the lowest (3.32, 95%CI: 2.03-5.43).

Among patients who took penicillin combinations, carbapenems, cephalosporins, tetracyclines, macrolides, fluoroquinolones, and trimethoprim-sulfamethoxazole, patients who were 65 years or older had a higher CDI ROR than those less than 65 years old (Figure [2](#F2){ref-type="fig"}). Among patients who took lincosamides, patients who were 65 years or older had a lower CDI ROR than those less than 65 years old.

The Cochran-Armitage Trend Test demonstrated that there was a significant relationship between the proportion of CDI reports in patients who took fluoroquinolones and the year of reporting (p\<0.0001). From 2004 to 2010, 2.3% of fluoroquinolone reports had CDI. From 2011 to 2017, 1.7% of fluoroquinolone reports had CDI.

Discussion
==========

Our antibiotic CDI association rank order was similar to previous meta-analyses [@B6]-[@B8]. Our results demonstrated significant CDI associations (from strongest to weakest) with lincosamides, monobactams, penicillin combinations, carbapenems, cephalosporins, tetracyclines, macrolides, fluoroquinolones, and trimethoprim-sulfonamides.

In a prior meta-analysis of antibiotics and the risk of community-associated CDI (CA-CDI), the risks from the highest to the lowest were: clindamycin, fluoroquinolones, CMCs, macrolides, trimethoprim- sulfonamides, and penicillins, with no effect of tetracycline on CDI risk [@B6]. In another prior meta-analysis of CA-CDI and antibiotics, the risks from the highest to the lowest were: clindamycin, fluoroquinolones, cephalosporins, penicillins, macrolides, and trimethoprim-sulfonamides, while no association was found between tetracyclines and CDIs [@B7]. Regarding hospital-acquired CDI (HA-CDI), a prior meta- analysis indicated that the associations from the strongest to weakest were: third-generation cephalosporins, clindamycin, second-generation cephalosporins, fourth-generation cephalosporins, carbapenems, trimethoprim-sulfonamides, fluoroquinolones, and penicillin combinations [@B8]. FAERS data do not specify whether CDI is community-associated or hospital-acquired; therefore, our results are likely a mixture of CA-CDI and HA-CDI.

The higher CDI RORs associated with clindamycin, penicillin combinations, and carbapenems may be due to their activity against anaerobes and disruption of gut flora [@B15]. Clindamycin had the highest CDI ROR in our study, which is consistent with the highest CDI risks associated with clindamycin in prior meta-analyses [@B6],[@B7]. Piperacillin- tazobactam had the second highest ROR in our study; the reasons might include the broad-spectrum antimicrobial activity of piperacillin-tazobactam and the great extent of gut flora disruption as a result [@B16],[@B17]. Trimethoprim-sulfonamides had the lowest CDI ROR among the antibiotic classes included in our study. In previous meta-analyses, trimethoprim-sulfonamides also had one of the lowest CDI risks [@B6]-[@B8].

Our results demonstrated that fluoroquinolones had a weaker association with CDI compared with most of the antibiotic classes included in the study, except for trimethoprim-sulfonamides. Prior meta- analyses have implicated fluoroquinolones as one of the highest risk antibiotics for CDI [@B6],[@B7]; however, these studies used data during the CDI epidemic that was associated with the fluoroquinolone-resistant ribotype 027 *Clostridium difficile* strain [@B18],[@B19]. A more recent meta-analysis by Vardakas et al. did not implicate fluoroquinolones as one of the highest risk antibiotics, which is consistent with our findings [@B20]. Given that ribotype 027 strains are now endemic in healthcare settings, our data suggest that fluoroquinolones might not be as important of a CDI risk factor as before considering the recent changes in CDI epidemiology [@B21]. A recent article published in 2017 demonstrated that a concomitant decline in inpatient fluoroquinolone use and the NAP1/027 strain may have contributed to the decrease in the incidence rate of long-term-care facility-onset CDI from 2011 to 2015 [@B22]. Our results from the Cochran-Armitage Trend Test also indicated that there was a trend of decrease in CDI risk with fluoroquinolones from 2004 to 2017.

In the subgroup analysis, the CDI ROR rank order in both subgroups (\< 65 years old and ≥ 65 years old) were similar to that in all patients. Our results showed that older patients had a higher CDI ROR among most of the antibiotic classes analyzed (Figure [2](#F2){ref-type="fig"}). It is known that CDI risk is higher in patients 65 years or older [@B23].

Knowledge of the CDI risk associated with antibiotic classes has important implications for antimicrobial stewardship. Therapeutic interchanges could be identified, especially for those patients who have a high baseline risk for CDI (e.g., elderly, frequent hospitalizations, and comorbid conditions). For example, to treat non-severe purulent skin and skin structure infections in patients with a high risk of CDI, trimethoprim-sulfamethoxazole could be preferred to clindamycin, considering the much lower CDI ROR of trimethoprim-sulfamethoxazole [@B24].

Limitations
-----------

A causal relationship between a drug and an adverse drug reaction (ADR) cannot be established by FAERS. The spontaneous and voluntary reporting of ADRs may lead to significant bias due to underreporting and lack of overall drug use data [@B25],[@B26]. The association between a drug and an ADR is confounded by concomitant drugs and comorbidities. Media attention and recent drug approval might affect the reporting behaviors. Furthermore, epidemiological shift in the circulating *C. difficile* strains in the United States might account for the weaker association between fluoroquinolones and CDI in our study; however, the FAERS study design does not permit us to investigate this hypothesis. Therefore, we believe the next step in this line of research will be to confirm these findings in a future case-control or cohort study.

Conclusions
===========

All antibiotic classes evaluated in the study were significantly associated with CDI. Lincosamides (e.g., clindamycin) had the highest CDI ROR and trimethoprim-sulfonamides had the lowest CDI ROR of all the antibiotic classes investigated in this study. Results from FAERS should be interpreted with caution in the context of data limitations. Antibiotic stewardship is needed to prevent CDI and to improve health outcomes.
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![**Reporting Odds Ratios (RORs) for *Clostridium difficile* infection with antibiotics.** † CI = confidence interval; CDI = *Clostridium difficile* infection](ijmsv16p0630g001){#F1}

![**Reporting Odds Ratios (RORs) for *Clostridium difficile* infection with antibiotics stratified by age.** † CI = confidence interval; CDI = *Clostridium difficile* infection; yrs = years](ijmsv16p0630g002){#F2}

###### 

A two by two contingency table for a drug (A) - ADR (X) combination

                ADR (X)   Other ADRs   Total
  ------------- --------- ------------ ---------
  Drug (A)      a         b            a+b
  Other drugs   c         d            c+d
  Total         a+c       b+d          a+b+c+d

† ADR = adverse drug reaction; ROR = (a/b)/(c/d); 95% Confidence Interval (CI) = e^ln(ROR)±1.96√(1/a+1/b+1/c+1/d)^

###### 

Gender and age information for patients on antibiotics

  Antibiotic Class/Antibiotic                        \% Female   Median age (IQR)
  -------------------------------------------------- ----------- ------------------
  **Lincosamides (clindamycin)**                     58          58 (28)
  **Monobactams (aztreonam)**                        56          55 (35)
  **Penicillin combinations**                        48          62 (28)
  Piperacillin-tazobactam                            39          64 (25)
  Amoxicillin-clavulanate                            54          60 (32)
  Ampicillin-sulbactam                               46          67 (33)
  **Carbapenems**                                    44          63 (29)
  Meropenem                                          44          61 (32)
  Ertapenem                                          44          69 (24)
  Imipenem-cilastatin                                46          63 (27)
  **Cephalosporins, monobactams, and carbapenems**   47          63 (34)
  **Third/fourth-generation cephalosporins**         49          62 (39)
  Cefepime                                           44          64 (20)
  Cefotaxime                                         39          44 (61)
  Ceftriaxone                                        51          63 (41)
  **Tetracyclines**                                  60          51 (35)
  Tetracycline                                       60          26 (32)
  Doxycycline                                        60          51 (35)
  **Macrolides**                                     61          54 (35)
  Erythromycin                                       63          55 (26)
  Clarithromycin                                     61          55 (33)
  Azithromycin                                       59          48 (41)
  **Fluoroquinolones**                               58          58 (27)
  Ofloxacin                                          43          68 (24)
  Ciprofloxacin                                      57          57 (28)
  Levofloxacin                                       61          59 (24)
  Moxifloxacin                                       55          55 (26)
  **Trimethoprim-sulfamethoxazole**                  45          60 (28)

† IQR = interquartile range
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